<!DOCTYPE HTML>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<title>VIKHI</title>
	<link rel="stylesheet" href="css/font-awesome/css/font-awesome.min.css" />

	<link rel="stylesheet" href="css/fonts/stylesheet.css" />
	<link rel="stylesheet" href="css/fonts/fonts.css" />
	<link rel="stylesheet" href="css/bootstrap/bootstrap.min.css" />
	<link rel="stylesheet" href="css/animat/animate.min.css" />
	<link rel="stylesheet" href="css/fancybox/jquery.fancybox.css" />
	<link rel="stylesheet" href="css/nivo-lightbox/nivo-lightbox.css" />
	<link rel="stylesheet" href="css/themes/default/default.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.carousel.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.theme.css" />
	<link rel="stylesheet" href="css/owl-carousel/owl.transitions.css">
	<link rel="stylesheet" href="css/style.css" />
	<link rel="stylesheet" href="css/responsive.css" />
	<link href="https://fonts.googleapis.com/css?family=Montserrat|Source+Sans+Pro" rel="stylesheet">
</head>
<body>

	<div class='preloader'><div class='loaded'>&nbsp;</div></div>

	<header id="home" class="header">
		<div class="main_menu_bg navbar-fixed-top">
			<div class="container">
				<div class="row">
					<div class="nave_menu">
					<nav class="navbar navbar-default">
					  <div class="container-fluid">
						<!-- Brand and toggle get grouped for better mobile display -->
						<div class="navbar-header">
						  <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
						  </button>
						  <a class="navbar-brand" href="index.html">
							<div class="logo">
								<img src="images/vikhiLOGOsm.png" alt="" height="30"/>
							</div>
						  </a>
						</div>

						<!-- Collect the nav links, forms, and other content for toggling -->
						<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">

						  <ul class="nav navbar-nav navbar-right">
							<li><a href="aspectos.html">1. General Aspects</a></li>
							<li class="active"><a href="recomendaciones.html">2. Recommendations</a></li>
							<li><a href="toxicidad00.html">3. Toxicities</a></li>
						  </ul>
						</div><!-- /.navbar-collapse -->
					  </div><!-- /.container-fluid -->
					</nav>
					</div>
				</div><!--Fin de row -->

			</div><!--Fin de container -->

		</div>
	</header> <!--Fin de header -->



	<section class="banner">
		<div class="container">
			<div class="row">
				<div class="main_banner_area text-center">
					<div class="col-md-12 col-sm-12">
						<div class="single_banner_text wow zoomIn" data-wow-duration="1s">
							<h2>General Recommendations for<br/>the management of Immunotherapy-Induced<br/>Toxicity in Cancer</h2>
							<br/>
							<div class="separator"></div>
							<h5>BASIC COURSE IN IMMUNOTHERAPY</h5>
						</div>
					</div>
				</div>
			</div>
		</div>
	</section><!-- Fin de Banner Section -->







	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">


					<p>Immunotherapy has a specific toxicity profile, which we will address later, and which is different from the one that the specialised oncology team was used to handling. For this reason, it is important to provide some guidelines for the care of patients who are receiving this type of treatment in order to minimise these side effects. Different clinical guidelines for its management have been developed over the last few years <span class="cursiva">(Postow, N Engl J Med. 2018; Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018)</span></p>
					<br/>
					<p>An institution with extensive experience in the use of these treatments is the Gustave Roussy cancer centre, which has shared its toxicity management guidelines for immunotherapy <span class="cursiva">(Champat, Ann Oncol 2016)</span>.</p>
					<br/>
					<div class="separator"></div>
					</div>
		   </div>
		 </div>
   </section>


	 <section>
	 	<div class="container">
	 		<div class="row">
	 			<div class="parrafo text-center wow fadeIn" data-wow-duration="1.5s">
	 				<h2>This management is based on 5 pillars:</h2>
	 			</div>
	 			<div class="wedo_content_area">

	 				<div class="col-md-6 col-sm-6 col-xs-12">
	 					<div class="contorno wow fadeIn" data-wow-duration="1s">
	 						<div class="single_right_text">
	 							<a href="#prevencion"><h4>2<span class="turquesa">.1</span> Prevention</h4></a>
	 						</div>
	 					</div>
	 				</div>

					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_right_text">
								<a href="#anticipacion"><h4>2<span class="turquesa">.2</span> Anticipation</h4></a>
							</div>
						</div>
					</div>

					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_right_text">
								<a href="#deteccion"><h4>2<span class="turquesa">.3</span> Detection</h4></a>
							</div>
						</div>
					</div>

					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_right_text">
								<a href="#tratamiento"><h4>2<span class="turquesa">.4</span> Treatment</h4></a>
							</div>
						</div>
					</div>

					<div class="col-md-6 col-sm-6 col-xs-12">
						<div class="contorno wow fadeIn" data-wow-duration="1s">
							<div class="single_right_text">
								<a href="#monitorizacion"><h4>2<span class="turquesa">.5</span> Monitoring</h4></a>
							</div>
						</div>
					</div>

	 			</div>
	 		</div>
	 	</div>
	 </section>






	 <section id="prevencion" class="franja">
 		<div class="overlay_franja">
 			<div class="container">
 				<div class="row">
 					<div class="col-md-12 col-sm-12 col-xs-12">
 						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
							<img src="images/corazonSM.png" alt="" height="40px"/> <br/><br/>
 							<h2>2<span class="negrita">.1</span> PREVENTION</h2>
 						</div>
 					</div>
 				</div>
 			</div>
 		</div>
 	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">


					<p><span class="decoradoBLUE">&nbsp;Knowing the spectrum of related toxicity&nbsp;</span> It is essential that professionals are aware of all the adverse events that may manifest, as well as their frequency, severity and chronology. Practically all the organs may present related adverse effects. Their description in clinical trials and in the form of clinical cases in literature helps us to detect them more easily <span class="cursiva">(Fig. 1)</span></p>
					</div>
			 </div>
		 </div>
	 </section>


	<section class="texto">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<div class="contenedor">
  				<img src="images/cuerpo01.png" alt="" class="imagen"/>
					<p class="piefoto">Fig. 1. Immunotherapy-associated toxicities</p>
  					<div class="sobreponer">
  					<img src="images/cuerpo02.png" alt="" class=""/>
  					</div>
					</div>
			  </div>
			</div>
	</section>

	<section class="texto">
		<div class="container">
			<div class="row">
				<div class="parrafo wow zoomIn" data-wow-duration="0.5s">


					<p><span class="decoradoBLUE">&nbsp;Identifying risk factors for their onset&nbsp;</span> It is important that a thorough history is taken to know if the following risk factors are present <span class="negritaBLUE">:</span></p>
					<br/><p><span class="negritaBLUE">Personal or family history of autoimmune diseases:</span> coeliac disease, Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, lupus, diabetes, thyroiditis, interstitial pneumonitis, sarcoidosis, pancreatitis, nephritis, idiopathic thrombocytopenic purpura, haemolytic anaemia, myasthenia gravis, multiple sclerosis, uveitis, retinitis, myocarditis, vasculitis, etc.</p>
					<br/><p>Their existence does not contraindicate the use of immunotherapy, but we must pay more attention to the symptoms presented by the patient because there is a greater likelihood that adverse effects will appear. <span class="cursiva">(Menzies, AnnOncol 2017, Johnson JAMA Oncol 2016)</span>.</p>

					<br/><p><span class="negritaBLUE">Usual medication and professional exposure.</span> Some drugs, such as antiarrhythmics, antihypertensives, antibiotics, anticonvulsants or antipsychotics, are associated with autoimmune diseases. (Xiao J Autoinmun 2014). Their administration in combination with immunotherapy may increase the possibility of related toxicities. For this reason, stricter monitoring is required. On the other hand, there are also drugs that may confer a protective effect through mechanisms of immune suppression (corticosteroids, allopurinol, NSAIDs). Some professional exposure may also increase the risk of autoimmune diseases, such as silicon and lupus or systemic sclerosis and exposure to mineral dust.</p>

					<br/><p>We would like to reiterate that the existence of this type of risk factor does not contraindicate immunotherapy use, but this is a factor to be taken into account.</p>

					<br/><p><span class="negritaBLUE">Infections by opportunistic pathogens.</span> Chronic infections induce a depletion of T cells by the expression of immune checkpoints such as PD1. The treatment of these checkpoints with inhibitors can cause an inflammatory reaction against this pathogen, empowering the one that causes it. For this reason, before starting treatment with one of these drugs, we must evaluate the previous history of infections, and risk of HIV or hepatitis virus.</p>

					<br/><p><span class="negritaBLUE">Tumour infiltration.</span> Immunotherapy-induced immune infiltration can increase peritumoural inflammation and be responsible for different types of toxicity depending on its location. It is sometimes difficult to make a differential diagnosis with tumour progression, but it has to be considered when there is no progression of other lesions.</p>

					<br/><p><span class="decoradoBLUE">&nbsp;Informing the patient and his/her regular doctors&nbsp;</span> The team, especially the nurse in the health education plan, is responsible for informing the patient of the potential risks and the importance of communicating any new symptoms or signs early on, and always managing it under professional supervision. The patient will be given recommendations to notify his or her regular doctors that he or she is receiving immunotherapy, and to facilitate a line of communication with the hospital team from the start, since early detection and, consequently, the initiation of treatment, are essential in reducing the duration and severity of toxicity.</p>

					<br/><p>Always carry out a physical examination and request an analytical and radiological assessment before starting this treatment type. Subsequently it is necessary to strictly monitor all potential toxicities, even 1 year after discontinuation of the therapy.</p>

					<br/><p><span class="decoradoBLUE">&nbsp;Providing special care in situations of greater fragility&nbsp;</span><span class="cursiva"> (Johnson, Cancer 2017)</span></p>
					<p><span class="decorado">&nbsp;&nbsp;1&nbsp;&nbsp;</span> Elderly patients</p>
					<p><span class="decorado">&nbsp;&nbsp;2&nbsp;&nbsp;</span> Impaired kidney and liver function</p>
					<p><span class="decorado">&nbsp;&nbsp;3&nbsp;&nbsp;</span> Pregnancy and breast-feeding</p>
					<p><span class="decorado">&nbsp;&nbsp;4&nbsp;&nbsp;</span> History of autoimmune diseases</p>
					<p><span class="decorado">&nbsp;&nbsp;5&nbsp;&nbsp;</span> History of chronic infection</p>


					<br/><p><span class="decoradoBLUE">&nbsp;Monitoring drug interactions&nbsp;</span> It is important that the health education plan explains to the patient that he or she must declare all medications being taken and any new ones that are prescribed in order to assess whether there is an interaction. <br/><p><span class="negritaBLUE">Monoclonal antibodies.</span> They are not metabolised by cytochrome p450, therefore there does not appear to be a risk of interaction.</p>
					<br/><p><span class="negritaBLUE">Corticosteroids or other immunosuppressants.</span> Their use is not recommended, but they can be used in the management of related toxicities.</p>
					<br/><p><span class="negritaBLUE">Anticoagulants or antiplatelet agents.</span> Caution is advised in their use.</p>
					<br/><p><span class="negritaBLUE">Drugs involved in the development of autoimmune diseases: antihistamines, NSAIDs, antibiotics (quinolones, β-lactams, cyclins), antimalarials (quinine), antiarrhythmics, antihypertensives (β-blockers), statins, anticonvulsants or antipsychotics.</span> Strict follow-up is recommended.</p>

					</div>
			 </div>
		 </div>
	 </section>


	 	 <section id="anticipacion" class="franja">
	  		<div class="overlay_franja">
	  			<div class="container">
	  				<div class="row">
	  					<div class="col-md-12 col-sm-12 col-xs-12">
	  						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
	  							<h2>2<span class="negrita">.2</span> ANTICIPATION</h2>
	  						</div>
	  					</div>
	  				</div>
	  			</div>
	  		</div>
	  	</section>



			<section class="texto">
				<div class="container">
					<div class="row">
						<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

							<p><span class="decoradoBLUE">&nbsp;Before starting immunotherapy&nbsp;</span> We recommend using the following checklist <span class="cursiva">(Fig. 2)</span></p>
						</div>
				 </div>
			 </div>
		 </section>




							<section class="texto">
									<div class="row">
										<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
											<div class="contenedor">
						  				<img src="images/checklist.png" alt="" class="imagen"/>
											<p class="piefoto">Fig. 2. baseline checklist</p>

											</div>
									  </div>
									</div>
							</section>


		 <section class="texto">
			   <div class="container">
						<div class="row">
							<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

							<p><span class="decoradoBLUE">&nbsp;During treatment&nbsp;</span> <br/><p>Before each administration of immunotherapy, the following must be checked <span class="negritaBLUE">:</span> complete blood count, kidney function, electrolytes, glycaemia, PCR, coagulation and liver function. They should be compared with baseline values.</p>
							<br/><p>Every 2 months TSH, proteinuria.</p>
							<br/><p>Imaging tests are not recommended in the absence of symptoms.</p>

							<br/><p><span class="decoradoBLUE">&nbsp;At the end of treatment&nbsp;</span> <br/><p>Clinical and laboratory tests are recommended every 3 months after the completion of the immunotherapy and subsequently every 6 months.</p>

							<br/><p><span class="decoradoBLUE">&nbsp;Overdose&nbsp;</span> <br/><p>No dose-limiting toxicity has been reached in the phase I studies. If overdose occurs, the patient should be monitored closely.</p>

							</div>
					 </div>
				 </div>
			 </section>


			 <section id="deteccion" class="franja">
		  		<div class="overlay_franja">
		  			<div class="container">
		  				<div class="row">
		  					<div class="col-md-12 col-sm-12 col-xs-12">
		  						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
										<img src="images/diagnostico.png" alt="" height="40px"/> <br/><br/>
										<h2>2<span class="negrita">.3</span> DETECTION</h2>
		  						</div>
		  					</div>
		  				</div>
		  			</div>
		  		</div>
		  	</section>

				<section class="texto">
					<div class="container">
						<div class="row">
							<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

								<p>When an adverse event appears during immune therapy, we have to consider 3 possible causes <span class="negritaBLUE">:</span></p>
								<br/><p><span class="decorado">&nbsp;&nbsp;1&nbsp;&nbsp;</span> Tumour progression,</p>
								<br/><p><span class="decorado">&nbsp;&nbsp;2&nbsp;&nbsp;</span> Toxicity to immunotherapy or</p>
								<br/><p><span class="decorado">&nbsp;&nbsp;3&nbsp;&nbsp;</span> Event not related to either of them.</p>

								<br/><p>Inexperience with these treatments and the low incidence of side effects from them means that many times we do not diagnose them at an early stage, and their prognosis worsens. On the other hand, trying to point all the new signs and symptoms towards immunotherapy, means that sometimes we do not detect other aetiologies and that patient progress is more unfavourable. <span class="negritaBLUE">Therefore, it is important to know how to make a correct differential diagnosis.</span></p>

								<br/><p>It is essential to know the adverse effects of each drug and the most common chronology of appearance<br/><span class="cursiva">(Fig 3)</span></p>

								<br/><p>There are toxicities that appear in the first two months <span class="negritaBLUE">:</span></p>
								<br/><p><span class="decorado">&nbsp;&nbsp;1&nbsp;&nbsp;</span> <span class="decorado">&nbsp;Early&nbsp;</span><span class="negrita">:</span> cutaneous events, gastrointestinal disorders and liver events</p>
								<br/><p><span class="decorado">&nbsp;&nbsp;2&nbsp;&nbsp;</span> <span class="decorado">&nbsp;Late (appear after two months)&nbsp;</span><span class="negrita">:</span> pulmonary, endocrine and kidney</p>

								<br/><p>However, they can start at any time (Weber, JClin Oncol 2012).</p>

								</div>
						 </div>
					 </div>
 			 	</section>


				<section id="tratamiento" class="franja">
 		  		<div class="overlay_franja">
 		  			<div class="container">
 		  				<div class="row">
 		  					<div class="col-md-12 col-sm-12 col-xs-12">
 		  						<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
										<img src="images/medicinas.png" alt="" height="40px"/> <br/><br/>
										<h2>2<span class="negrita">.4</span> TREATMENT</h2>
										<br/><br/>

										<p><span class="cursiva">(Champiat, AnnOncol 2016, Kumar Frontiers in Pharmacology 2017, Bristol-Myers REMS 2012, Haanen, Ann Oncol. 2017; Thompson. J Natl Compr Canc Netw. 2018; Brahmer. J Clin Oncol. 2018)</span></p>
 		  						</div>
 		  					</div>
 		  				</div>
 		  			</div>
 		  		</div>
 		  	</section>


				<section class="texto">
					<div class="container">
						<div class="row">
							<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

								<p>General management of the adverse effects of immunotherapy follows the following algorithm<span class="negritaBLUE">:</span></p>

								</div>
						 </div>
					 </div>
 			 	</section>


		<section class="tabla">
			<div class="container">
				<div class="row">
					<div class="wow zoomIn" data-wow-duration="0.5s">


				<table class="vikhi-tabla">
						<tr>
							<th><p>Grade</p></th>
							<th><p>Category</p></th>
							<th><p>Corticosteroids</p></th>
							<th><p>Other immunosuppressants</p></th>
							<th><p>Immunotherapy</p></th>
						</tr>
						<tr>
							<td width="5%"><p>1</p></td>
							<td><p>Outpatient</p></td>
							<td><p>Not recommended</p></td>
							<td><p>Not recommended</p></td>
							<td><p>Continue</p></td>
						</tr>
						<tr>
							<td width="5%"><p>2</p></td>
							<td><p>Outpatient</p></td>
							<td><p>Topical corticosteroids or oral corticosteroids of Prednisone 0.5-1 mg/kg/day or equivalent</p></td>
							<td><p>Not recommended</p></td>
							<td><p>Temporarily suspend (until toxicity is &lt;grade 1)</p></td>
						</tr>
						<tr>
							<td width="5%"><p>3</p></td>
							<td><p>Hospitalised</p></td>
							<td><p>Oral or IV corticosteroids of Prednisone 1-2 mg/kg/day or equivalent for 3 days then reduce to 1 mg/kg/day</p></td>
							<td><p>Consider for patients with no improvement after 3-5 days of corticosteroid therapy<br/>Comment with the medical product that applies</p></td>
							<td><p>Suspend (until toxicity is &lt;grade 1) and evaluate its reintroduction depending on the benefit/risk</p></td>
						</tr>
						<tr>
							<td width="5%"><p>4</p></td>
							<td><p>Hospitalised/consider critical unit</p></td>
							<td><p>IV corticosteroids<br/>Prednisone<br/>1-2 mg/kg/day or equivalent for 3 days then reduce to 1 mg/kg/day</p></td>
							<td><p>Consider for patients with no improvement after 3-5 days of corticosteroid therapy<br/>Comment with the medical product that applies</p></td>
							<td><p>Discontinue permanently</p></td>
						</tr>
				</table>

					</div>
				</div>
			</div>
		</section>

		<section class="texto">
			<div class="container">
				<div class="row">
					<div class="parrafo wow zoomIn" data-wow-duration="0.5s">

						<p><span class="decoradoBLUE">&nbsp;Corticosteroid therapy&nbsp;</span> Before starting, it is recommended to rule out an associated infection, as well as to combine with antibiotic prophylaxis with Trimethoprim/Sulfamethoxazole (400 mg/day) if they are going to be used for a long time <span class="cursiva">(National Comprehensive Cancer Network) <a href="http://www.nccn.org/professionals/physician_gls/pdf/infections.pdf">(Prevention and treatment of cancer-related infections, version 1.2018, December 1, 2017)</a></span>. Withdrawal should take place gradually over at least one month to avoid a new onset of the symptoms or worsening of them <span class="cursiva">(Fay, Expert Review of Quality of Life in Cancer Care, 2016)</span>.</p>
						<br/>
						<p>If evolution is not favourable despite the use of corticosteroids, the possibility of adding an immunosuppressant (Infliximab 5 mg/kg, repeating at 2 weeks if the symptoms persist) should be assessed with the specialist of the affected organ. If this has to be done, a TB skin test (PPD) should always be performed on the patient (Horvat TZ, J Clin Oncol 2015).</p>
						<br/> <br/><p><span class="decoradoBLUE">&nbsp;When to restart or finalise immunotherapy&nbsp;</span> There is no clear correlation between the dose and duration of immunotherapy and its efficacy, which is why it is important to suspend it temporarily or permanently if we suspect toxicity. Long-term responses have even been seen after its discontinuation.</p>
						<br/><p><span class="decorado">&nbsp;Definitive discontinuation&nbsp;</span> Is necessary if there is<span class="negrita">&nbsp;:&nbsp;</span> <br/><p class="izquierda"><span class="decorado ">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Grade 4 toxicity<span class="negrita">*</span> or</p>
						<br/><p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Recurrent grade 3 toxicity<span class="negrita">*</span> or</p>
						<br/><p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Grade 2 toxicity that does not progress favourably in 3 months despite correct treatment</p>
						<br/><p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Inability to reduce the dose of glucocorticoids to 7.5 mg of prednisone/day or equivalent in patients treated with antiCTLA4 and less than 10 mg/day in 12 weeks in antiPD1</p>
						<br/><p class="izquierda"><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Grade 2-4 ocular toxicity that does not improve to grade 1 after 2 weeks of treatment with topical immunosuppressants or that requires systemic treatment.</p>
						<br/><p><span class="negrita">*</span> <span class="cursiva">Endocrinological toxicities that are controlled with hormone replacement therapy do not require definitive suspension of immunotherapy</span></p>

						<br/><p><span class="decorado">&nbsp;Temporary discontinuation&nbsp;</span> Immunotherapy can be restarted if<span class="negrita">&nbsp;:&nbsp;</span> <br/><p><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Toxicity decreases to grade &lt; 1 and</p>
						<br/><p><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> The recommended dose of corticosteroids is &lt;10 mg prednisone/day or</p>
						<br/><p><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> equivalent and</p>
						<br/><p><span class="decorado">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span> Other immunosuppressive treatment is not required</p>
						<br/><p><span class="negrita">*</span> <span class="cursiva">Dose adjustment is not recommended</span></p>


						<br/><p>One of the most important aspects in clinical practice is safety when reintroducing the treatment once the adverse effect has been resolved.</p>
						<br/><p>An absolute contraindication to restart it is if the patient has presented a life-threatening toxicity, particularly cardiac, pulmonary or neurological.</p>
						<br/><p><span class="negritaBLUE">When to consult other specialists?</span> Given the inexperience in the use of these drugs, it is important to value the opinion of other specialists, since in the differential diagnosis of the symptoms presented by these patients, there may be incidental entities that a specialist can detect with a greater deal of understanding. Whenever the diagnosis and management of these toxicities start to become complex, a specialist should be consulted.</p>

						</div>
				 </div>
			 </div>
		</section>



		<section id="monitorizacion" class="franja">
			<div class="overlay_franja">
				<div class="container">
					<div class="row">
						<div class="col-md-12 col-sm-12 col-xs-12">
							<div class="main_franja_content text-center wow fadeIn" data-wow-duration="2s">
								<img src="images/lupa.png" alt="" height="40px"/> <br/><br/>
								<h2>2<span class="negrita">.5</span> MONITORING</h2>
							</div>
						</div>
					</div>
				</div>
			</div>
		</section>


		<section class="texto">
			<div class="container">
				<div class="row">
					<div class="parrafo wow zoomIn" data-wow-duration="0.5s">
					<p><span class="decoradoBLUE">&nbsp;Resolution of toxicities&nbsp;</span> The time required to resolve these toxicities varies according to the type of toxicity. Gastrointestinal, hepatic and renal toxicities improve rapidly with immunosuppressive treatment; however, cutaneous and endocrine toxicities are much slower to resolve, even leaving permanent alterations that require replacement therapy.</p>
					<br/><p>Severe skin, endocrine and gastrointestinal toxicities are the most resistant to immunosuppressive treatment.</p>
					<br/><p><span class="decoradoBLUE">&nbsp;Impact of immunosuppressive agents on response&nbsp;</span> So far, and in the absence of prospective studies that confirm this, it has not been demonstrated that the use of immunosuppressive treatment in the context of toxicity associated with immunotherapy impairs the response to it.</p>
					<br/><p><span class="decoradoBLUE">&nbsp;Complications derived from immunosuppressive treatment&nbsp;</span> Its prolonged use may increase the risk of opportunistic infections such as pulmonary aspergillosis, reactivation of tuberculosis, cytomegalovirus (CMV) infections or Fournier gangrene. The team must be aware of this in order to detect them as early as possible. It is also important to consider other complications derived from the prolonged use of corticosteroids, such as hyperglycaemia/diabetes mellitus, proximal myopathy and suppression of the hypothalamic-pituitary axis.</p>

						</div>
				 </div>
			 </div>
		</section>







		<footer id="footer" class="footer">
			<div class="container">
				<div class="row">
					<div class="main_footer text-center wow zoomIn" data-wow-duration="1s">
						<p class="centrado"><a href="https://www.e-oncologia.org/"><img src="images/LOGOeonco.png" alt="" height="22px"/></a></p>
					</div>
				</div>
			</div>
		</footer>

	<!-- STRAT SCROLL TO TOP -->

	<div class="scrollup">
		<a href="#"><img src="images/up.png" alt=""/></a>
	</div>






	<script type="text/javascript" src="js/jquery/jquery.js"></script>

	<script type="text/javascript" src="js/script.js"></script>

	<script type="text/javascript" src="js/bootstrap/bootstrap.min.js"></script>

	<script type="text/javascript" src="js/fancybox/jquery.fancybox.pack.js"></script>

	<script type="text/javascript" src="js/nivo-lightbox/nivo-lightbox.min.js"></script>

	<script type="text/javascript" src="js/owl-carousel/owl.carousel.min.js"></script>





	<script type="text/javascript" src="js/jquery-easing/jquery.easing.1.3.js"></script>
	<script type="text/javascript" src="js/wow/wow.min.js"></script>
	<!--<script type="text/javascript" src="js/counterup/counterup.min.js"></script>-->

	<!--<script src="http://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>-->
	<!--<script type="text/javascript" src="js/counterup/jquery.counterup.min.js"></script>-->


	<script type="text/javascript" src="js/isotop/isotope.min.js"></script>
	<script type="text/javascript" src="js/isotop/isotop.function.js"></script>

	<script type="text/javascript" src="js/masonry/masonry.min.js"></script>

	<script type="text/javascript" src="js/mixitup/jquery.mixitup.min.js"></script>
	<script type="text/javascript" src="js/masonry/masonry.pkgd.min.js"></script>
</body>
</html>
